A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one.
Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose 3 blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.
The treatment of raised blood pressure has changed substantially in the past 40 years.' In the 1950s the first drugs for lowering blood pressure were used primarily to treat individuals with malignant or accelerated hypertension. This was often a symptomatic disorder characterised by very high blood pressure, which was usually fatal if left untreated. Since the 1960s numerous clinical trials have shown that treating less extreme cases of raised blood pressure reduces patients' risks of developing cardiovascular disease mainly stroke, coronary heart disease, and renal disease. These trials have led to a progressive lowering of the blood pressure at which doctors start antihypertensive treatment.
Most people who are now treated for raised blood pressure do not have symptomatic disease. Their raised blood pressure, however, increases their risk of developing cardiovascular disease in the future relative to similar individuals with lower blood pressure. Thus high blood pressure is a risk factor for disease but not a disease in itself. Only a small proportion of people with Some people with raised blood pressure but no other major risk factor for cardiovascular disease may have a low absolute risk of developing the disease. For example, of 100 women aged 60 with mildly raised blood pressure but no other important risk factor for cardiovascular disease, 10 at most are likely to have a major cardiovascular event (stroke, myocardial infarction, or coronary death) in the next 10 years.3 Thus 900 o of the women would remain free of disease for the 10 years. Most current clinical guidelines for the management of raised blood pressure, however, are based largely on blood pressure while other risk factors affecting absolute risk, although they are considered, are given less emphasis.i This means that a 60 year old woman with a diastolic blood pressure of 100 mm Hg but no other risk factor an absolute risk of cardiovascular disease of about 10% in 10 years'-may meet the criteria for treatment whereas a 70 year old man with multiple risk factors but a diastolic blood pressure of 95 mm Hg an absolute risk of about 50% in 10 years may not.
Costs and benefits oftreatment
Clinical trials suggest that whatever the initial absolute risk of cardiovascular disease, reducing blood pressure will reduce the relative risk of disease by about the same proportion.7 Reviews of randomised trials indicate that lowering diastolic blood pressure by about 5-6 mm Hg (and systolic blood pressure by about 10 mm Hg) reduces the relative risk of stroke by about 35-40% and of coronary heart disease by 15-20%. Therefore, if lowering blood pressure by this amount would reduce the overall risk of a cardiovascular event by about one third in both the 60 year old woman and 70 year old man described above, then treating the woman would reduce her absolute risk in 10 years by about 3% whereas treating the man would reduce his absolute risk by about 17% (see table) .
Treating people with raised blood pressure but a low absolute risk of cardiovascular disease raises the question of whether such people gain sufficient benefits to outweigh the possible side effects of treatment. Given the need to manage limited resources efficiently, the cost effectiveness of treatment is also an important consideration. If, say, 100 women require treatment for 10 years to prevent three cardiovascular events the cost of preventing each event will be much higher BMJ VOLUME 307
10 JuLY 1993 than that of treating 100 men at high risk and preventing about 17 events. The cost effectiveness of treatment will depend not only on the absolute risk but also on the choice of medication because of the different costs and side effects of various drugs. Unfortunately only limited information about cost effectiveness is available for methods of lowering blood pressure, and it is therefore premature to base guidelines for treatment primarily on cost effectiveness.
In the past 20 years the introduction of better tolerated but more expensive drugs and the progressive lowering of the blood pressure at which treatment is recommended have meant that the number of people treated and the costs of treatment have increased substantially. In New Zealand the current annual cost of drugs for lowering blood pressure is about $NZ 80-100 million (about 15% of the total national drug bill). Between 15% and 20% of middle aged New Zealanders and more than a quarter of those aged over 65 regularly take drugs for lowering blood pressure.8
Recommendations
In this report we attempt to quantify the level of absolute risk of cardiovascular disease at which treatment should be considered more explicitly than has been done in previous guidelines. The recommendations are based on the premise that, in most cases, raised blood pressure is a risk factor for cardiovascular disease rather than a disease in its own right. They do not cover in detail the management of accelerated hypertension or secondary hypertension. Some of the issues raised, particularly those relating to the absolute risk at which treatment should be contemplated and how much individuals or the public health services should pay to prevent a disease event, require public debate.
OBJECTIVES OF TREATING RAISED BLOOD PRESSURE * The main objective of reducing blood pressure in a person with raised blood pressure is to reduce the absolute risk of premature death and disease, primarily by decreasing the risk of coronary heart disease and stroke. * Treatment to lower blood pressure is indicated when the treatment's benefits are thought to outweigh its adverse effects and when its cost effectiveness is similar to that of other accepted interventions. INDIVIDUALS 
Background
The publication of the report of the Physicians for Human Rights (UK) and Johannes Wier Foundation on apartheid and health care' provides an opportunity to review policy in relation to the boycott of South African health services and related institutions.
The boycott, nominally known as the "academic boycott" but extending beyond academics and their institutions, was introduced at the request of the African National Congress and was supported by its allies, both in South Africa and abroad. The African National Congress considered it necessary to institute a set of measures to isolate South Africa in the economic, military, cultural, sporting, and academic spheres of life. It was argued that this would increase pressure for change from business as well as from sports enthusiasts and academics by making it clear that apartheid was totally unacceptable to the world community and that the penalties for maintaining the status quo would increase. At the same time, trade and military sanctions would weaken the ability of the state to repress opposition within the country and to destabilise the surrounding states. The African National Congress argued that no part of society should be spared by the boycott.
In the health sector, apartheid ensured the inequitable distribution and quality of health care between black and white, urban and rural, wealthy and poor.2 The training of medical and allied health personnel was deeply divided: medical schools were largely segregated by race, with even the more liberal schools including only a minority of black students and having even fewer blacks on their staff. Furthermore, the establishment medical bodies, such as the Medical Association of South Africa and the South African Medical and Dental Council, played deeply divisive roles by not challenging the impact of apartheid in health and even giving tacit support to doctors who explicitly abused their ethical responsibilities, such as the doctors involved in the case of Stephen Biko. 3 A policy of isolation was seen as the mechanism whereby overseas doctors could make clear their absolute abhorrence of apartheid. It would also encourage health professionals in South Africa to challenge apartheid and make the state realise that only fundamental change would allow their acceptance into the world community. Any benefits from intemational medical exchange would be far outweighed by progress towards ending apartheid.
Opponents of the African National Congress's stance took the view that the medical ethic of internationalism, the free exchange of knowledge, and the commitment of care for patients from all backgrounds takes precedence over political campaigning. It was argued that the strategy may be counterproductive and lead to acceptance of the status quo. 4 
